ELEV vs. SNTI, ZURA, CLLS, CLYM, IZTC, OCX, ADAG, CRVO, TCRX, and IMAB
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Senti Biosciences (SNTI), Zura Bio (ZURA), Cellectis (CLLS), Climb Bio (CLYM), Invizyne Technologies (IZTC), OncoCyte (OCX), Adagene (ADAG), CervoMed (CRVO), TScan Therapeutics (TCRX), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry.
Elevation Oncology vs.
Senti Biosciences (NASDAQ:SNTI) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Senti Biosciences had 3 more articles in the media than Elevation Oncology. MarketBeat recorded 4 mentions for Senti Biosciences and 1 mentions for Elevation Oncology. Senti Biosciences' average media sentiment score of 0.00 beat Elevation Oncology's score of -1.00 indicating that Senti Biosciences is being referred to more favorably in the media.
Elevation Oncology received 34 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 66.10% of users gave Elevation Oncology an outperform vote while only 45.45% of users gave Senti Biosciences an outperform vote.
Senti Biosciences presently has a consensus price target of $12.00, indicating a potential upside of 293.44%. Elevation Oncology has a consensus price target of $3.39, indicating a potential upside of 954.74%. Given Elevation Oncology's higher probable upside, analysts clearly believe Elevation Oncology is more favorable than Senti Biosciences.
Senti Biosciences has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
Elevation Oncology has lower revenue, but higher earnings than Senti Biosciences. Elevation Oncology is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Elevation Oncology's return on equity of -59.73% beat Senti Biosciences' return on equity.
Summary
Elevation Oncology beats Senti Biosciences on 10 of the 16 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Elevation Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:ELEV) was last updated on 5/23/2025 by MarketBeat.com Staff